title: Optimal treatment for T1-3NOMO small cell lung cancer: surgery plus adjuvant chemotherapy.
abstract: To improve treatment results in patients with surgically resectable T1-3NOMO small cell lung cancer, 16 patients were randomized to receive either neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy (cyclophosphamide, epirubicin, and etoposide). The overall survival is 45% at a median follow-up of 28.5 months. Patients treated with surgery plus adjuvant chemotherapy (n = 8) showed a significantly higher median and overall survival, proportion of 2-year survivors, and lower systemic relapse rate. These results indicate that the optimal treatment for T1-3NOMO small cell lung cancer is represented by the combination of surgery plus adjuvant chemotherapy.
authors.affiliation: Service of Thoracic Surgery, University of Pisa, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Macchiarini
authors.forename: A
authors.initials: A
authors.lastname: Mussi
authors.forename: F
authors.initials: F
authors.lastname: Basolo
authors.forename: J
authors.initials: J
authors.lastname: Bruno
authors.forename: C A
authors.initials: CA
authors.lastname: Angeletti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
chemical_list: D015251:Epirubicin; D005047:Etoposide; D003520:Cyclophosphamide